Cancer Epidemiology
Volume 35, Issue 2 , Pages 112-119 , April 2011

Characteristics and survival associated with ovarian cancer diagnosed as first cancer and ovarian cancer diagnosed subsequent to a previous cancer

  • Zahava Berkowitz

      Affiliations

    • Corresponding Author InformationCorresponding author at: Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Epidemiology and Applied Research Branch, 4770 Buford Highway NE, MS K-55, Atlanta, GA 30341-3724, USA. Tel.: +1 770 488 4881; fax: +1 770 488 4639.
    • ,
  • Sun Hee Rim
    • ,
  • Lucy A. Peipins

,Accepted 1 July 2010.

References 

  1. Ryerson AB, Eheman C, Burton J, McCall N, Blackman D, Subramanian S, et al. Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer. Obstet Gynecol. 2007;109(5):1053–1061
  2. U.S. Cancer Statistics Working Group. United States cancer statistics: 1999–2005 incidence and mortality web-based report. Atlanta, GA: Department of Health and Human Services, Center for Disease Control and Prevention; Washington, DC: National Cancer Institute; 2009. Available at: www.cdc.gov/uscs.
  3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66
  4. Chan JK, Cheung M, Husain A, Teng NN, West D, Whittemore AS, et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol. 2006;108(3 Pt 1):521–528
  5. Hankinson S, Danforth K. Ovarian cancer. In:  Schottenfeld D,  Fraumeni J editor. Cancer epidemiology and prevention. 3rd ed.. New York: Oxford University Press; 2007;p. 1013–1026
  6. Modugno F, Ness R, Wheeler J. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. Ann Epidemiol. 2001;11(8):568–574
  7. Kurian AW, Balise R, McGuire V, Whittemore A. Histologic types of epithelial ovarian cancer: have they different risk factors?. Gynecol Oncol. 2005;96(2):520–530
  8. Tung KH, Goodman MT, Wu AH, McDuffie K, Wilkens AR, Kolonel LM, et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol. 2003;158(7):629–638
  9. Bermejo J, Rawal R, Hemminki K. Familial association of specific histologic types of ovarian malignancy with other malignancies. Cancer. 2004;100(7):1507–1514
  10. Kirova YM, De Rycke Y, Gambotti L, Pierga JY, Asselain B, Fourquet A. Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer. 2008;98(5):870–874
  11. Soerjomataram I, Louwman W, Lemmens V, de Vries E, Klokman W, Coebergh J. Risks of second primary breast and urogenital cancer following female breast cancer in the south of The Netherlands, 1972–2001. Eur J Cancer. 2005;41(15):2331–2337
  12. Hall HI, Jamison P, Weir HK. Second primary ovarian cancer among women diagnosed previously with cancer. Cancer Epidemiol Biomarkers Prev. 2001;10(9):995–999
  13. National Cancer Institute Surveillance Research Program . Surveillance epidemiology and end result (SEER). Bethesda, MD: National Cancer Institute; 2007 April;Available at: URL: www.seer.cancer.gov/seerstat
  14. The SEER program code manual. Report No.: 3rd ed. Bethesda, MD: National Cancer Institute; 1998.
  15. Curtis R, Ries L. Methods. In:  Curtis RE,  Freedman DM,  Ron E,  Ries LAG,  Hacker DG,  Edwards BK,  Tucker MA,  Fraumeni JF editor. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. Ref type: serial (book, monograph). Bethesda, MD: National Cancer Institute; 2006;NIH Publ. No. 05-5302 [Chapter 2]
  16. Young JJ, Roffers S, Ries L, Fritz A, Hurlbut A. SEER summary staging manual-2000: codes and coding instructions. NIH Pub. No. 01-4969. Bethesda, MD: National Cancer Institute; 2001;
  17. Allison PD. Survival analysis using the SAS system. A practical guide. Cary, NC: SAS Institute Inc.; 1995;
  18. Collet D. Modeling survival data in medical research. 1st ed.. Chapman & Hall/CRC; 1994;
  19. Cress R, O’Malley C, Leiserowitz G, Campleman S. Patterns of chemotherapy use for women with ovarian cancer: a population-based study. J Clin Oncol. 2003;21:1530–1535
  20. Ji J, Forsti A, Sundquist J, Lenner P, Hemminki K. Survival in ovarian cancer patients by histology and family history. Acta Oncol. 2008;47:1133–1139
  21. Choi M, Fuller C, Thomas C, Wang S. Conditional survival in ovarian cancer: results from the SEER dataset 1988–2001. Gynecol Oncol. 2008;109(2):203–209
  22. Brun JL, Feyler A, Chene G, Saurel J, Brun G, Hocke C. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol. 2000;78(1):21–27
  23. Ikeda K, Sakai K, Yamamoto R, Hareyama H, Tsumura N, Watari H. Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer. Int J Gynecol Cancer. 2003;13(6):776–784
  24. Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. JNCI. 2006;98(3):172–180
  25. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72:278–287
  26. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107(1):77–85
  27. Lynch H, Lanspa S, Smyrk T, Boman B, Watson P, Lynch J. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II): genetics, pathology, natural history, and cancer control, part I. Cancer Genet Cytogenet. 1991;53:143–160
  28. Malander S, Rambech E, Kristoffersson U, Halvarsson B, Ridderheim M, Borg A, et al. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol. 2006;101(2):238–243
  29. Newman B, Millikan R, King M. Genetic epidemiology of breast and ovarian cancers. Epidemiol Rev. 1997;19:69–79
  30. Rubin S, Blackwood M, Bandera C, Behbakht K, Benjamin I, Rebbeck T, et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol. 1998;178:670–677
  31. Schottenfeld D, Beebe-Dimmer J. Multiple primary cancers. In:  Schottenfeld D,  Fraumeni JF editor. Cancer epidemiology and prevention. 3rd ed.. New York: Oxford University Press Inc.; 2006;p. 1269–1280
  32. Welcsh P, King M. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001;10:701–713
  33. Anderson H, Bladstron A. Familial breast and ovarian cancer: a Swedish population-based register study. Am J Epidemiol. 2000;152(12):1154–1163
  34. Gutman M, Cnaan A. Are malignant melanoma patients at higher risk for a second cancer?. Cancer. 1991;68(3):660–665
  35. Robinson E, Adler A, Nasrallah S, Kuten A, Steiner M, Rennert G, et al. Clinical characteristics of patients with a second primary tumor in the endometrium or ovary. Eur J Gynaecol Oncol. 1995;16:195–198
  36. Cook L, Weiss N, Doherty J, Chen C. Endometrial cancer. In:  DiSaia P,  Creasman W editor. Clinical gynecologic oncology. 7th ed.. Philadelphia: Elsevier Inc.; 2007;
  37. Fathalla M. Incessant ovulation—a factor in ovarian neoplasia?. Lancet. 1971;2:163
  38. Mills P, Riordan D, Cress R, Goldsmith D. Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. Cancer Detect Prev. 2005;29:124–132
  39. Riman T, Persson I, Nilsson S. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin Endocrinol. 1998;49:695–707
  40. Rossouw J, Anderson G, Prentice R. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333
  41. Althuis MD, Scoccia B, Lamb EJ, Moghissi KS, Westhoff CL, Mabie JE, et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. Am J Obstet Gynecol. 2005;193(3 Pt 1):668–674
  42. Lacey JV, Brinton L, Leitzmann MF, Mouw T, Hollenbeck A, Schatzkin A, et al. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst. 2006;98(19):1397–1405
  43. Morch L, Lokkegaard E, Andreasen A, Kruger-Kjaer S, Lidegaard O. Hormone therapy and ovarian cancer. JAMA. 2009;302:298–305
  44. Boice J, Engholm G, Kleinerman R. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res. 1988;116:3–55
  45. Wingo PA, Jamison PM, Hiatt RA, Weir HK, Gargiullo PM, Hutton M, et al. Building the infrastructure for nationwide cancer surveillance and control—a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control. 2003;14:175–193

☆ The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

PII: S1877-7821(10)00126-8

doi: 10.1016/j.canep.2010.07.001

Cancer Epidemiology
Volume 35, Issue 2 , Pages 112-119 , April 2011

Article Tools

* Image Usage & Resolution